Refractory Clinical Trials in Hangzhou, Zhejiang
36 recruitingHangzhou, Zhejiang, China
Showing 1–20 of 36 trials
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Refractory/Recurrent Peripheral T-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University45 enrolled1 locationNCT07164560
Recruiting
Not Applicable
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
Poorly Differentiated Thyroid CarcinomaAdvanced Thyroid CarcinomaRadioiodine-refractory Differentiated Thyroid Cancer
Zhejiang Provincial People's Hospital94 enrolled1 locationNCT07068542
Recruiting
Phase 1
Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma
Refractory/Relapsed B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University48 enrolled1 locationNCT07398963
Recruiting
Phase 1
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Advanced Solid TumorRefractory Non-Hodgkin Lymphoma
FBD Biologics Limited80 enrolled8 locationsNCT05892718
Recruiting
Phase 3
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.464 enrolled6 locationsNCT07361003
Recruiting
Phase 2
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting
Phase 1
Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Second Affiliated Hospital, School of Medicine, Zhejiang University48 enrolled1 locationNCT07263906
Recruiting
Phase 3
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.324 enrolled19 locationsNCT06082102
Recruiting
Phase 2
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University72 enrolled1 locationNCT06621212
Recruiting
Phase 2
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.100 enrolled11 locationsNCT04684147
Recruiting
Phase 1
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Advanced Solid TumorsRefractory LymphomaRelapsed Hematologic Malignancy
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.111 enrolled8 locationsNCT06615193
Recruiting
Phase 2
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
Zhejiang Cancer Hospital41 enrolled1 locationNCT06086197
Recruiting
Phase 4
Clinical Study of OR for Second-line Treatment of Refractory MZL
OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
Lixia Sheng39 enrolled3 locationsNCT06134284
Recruiting
Phase 2
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University34 enrolled1 locationNCT06434662
Recruiting
Phase 1
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
Advanced Solid TumorNon-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma Refractory
Tarapeutics Science Inc.26 enrolled1 locationNCT05650580
Recruiting
Early Phase 1
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Acute Lymphoblastic Leukemia, in RelapseMultiple Myeloma in RelapseMultiple Myeloma, Refractory+3 more
Zhejiang University120 enrolled1 locationNCT04603872